Quanterix Corporation
NASDAQ:QTRXMedical - Devices
+$0.46 today
- Market cap
- $98.28M
- Beta
- 1.12
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$2.22
Volume 3.54M
Average 1.15M
QTRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Quanterix CorporationNASDAQ: QTRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $7.32M fell 27.0% year over year, behind the -3.4% change in trailing-twelve-month research & development. Sequentially, it fell 16.7% from the prior quarter. Over 3 fiscal years it compounded at +10.2% a year.
Context
- Research & development amounted to 25.9% of revenue in FY2025, up 3.0 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -27.0% toward the trailing-twelve-month pace of -3.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 35.92M USD
- Year-over-year change
- +15.6%
- 4-year CAGR
- +6.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.92M | +15.6% |
| FY2024 | 2024-12-31 | 31.08M | +19.3% |
| FY2023 | 2023-12-31 | 26.06M | -2.8% |
| FY2022 | 2022-12-31 | 26.81M | -5.5% |
| FY2021 | 2021-12-31 | 28.38M | — |
Research & Development vs competitors
How QTRX compares with its peers on the latest reported figures
- QTRX's LTM Mar 2026 research & development of $33.21M is the 2nd highest of the 11 companies compared; the peer median is $16.6M.
- Its year-over-year change of -3.4% is the 5th highest of 11, against a peer median of -7.4%.
- Research & development amounts to 22.9% of revenue for QTRX, versus a peer median of 18.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $33.21M | -3.4% | +10.2% | 22.9% | |
| LTM Mar 2026 | $32.9M | -13.4% | -7.3% | 80.8% | |
| LTM Mar 2026 | $21.34M | -31.8% | -24.3% | 18.1% | |
| LTM Mar 2026 | $20.46M | +7.3% | -4.0% | 5.8% | |
| LTM Dec 2025 | $19.24M | -4.7% | -10.1% | 147.7% | |
| LTM Mar 2026 | $13.97M | -23.1% | -7.7% | 24.2% | |
| LTM Mar 2026 | $12.72M | -28.5% | -13.9% | 16.0% | |
| LTM Mar 2026 | $11.7M | +10.5% | +3.8% | 19.8% | |
| LTM Mar 2026 | $2.8M | -10.1% | +3.8% | 1.0% | |
| LTM Mar 2026 | $1.81M | +151.4% | +33.6% | 4.1% | |
| Peer median (excluding QTRX) | $16.6M | -7.4% | -5.7% | 18.1% | |
Competitors are the stored peer set for QTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 110.56M | 105.52M | 121.14M | 135.44M | 138.65M |
| Cost of Revenue | 45.78M | 60.16M | 48.14M | 54.32M | 73.94M |
| Gross Profit | 64.77M | 45.36M | 73M | 81.12M | 64.72M |
| Gross Margin | 58.6% | 43.0% | 60.3% | 59.9% | 46.7% |
| Research & Development | 28.38M | 26.81M | 26.06M | 31.08M | 35.92M |
| Selling, General & Admin | 92.91M | 91.85M | 92.82M | 104.64M | 138.85M |
| Operating Expenses | 121.29M | 149.63M | 118.99M | 133.74M | 174.53M |
| Depreciation & Amortization | 4.88M | 5.41M | 8.29M | 8.36M | 18.93M |
| EBITDA | (50.3M) | (67.89M) | (36.37M) | (29.74M) | (93.35M) |
| EBITDA Margin | -45.5% | -64.3% | -30.0% | -22.0% | -67.3% |
| Operating Income | (56.52M) | (104.26M) | (45.99M) | (52.62M) | (109.82M) |
| Operating Margin | -51.1% | -98.8% | -38.0% | -38.8% | -79.2% |
| Interest Income | 0 | 5.13M | 15.84M | 14.66M | 8.57M |
| Interest Expense | 403K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 937K | 4.85M | 18.36M | 14.52M | (2.46M) |
| Income Before Tax | (55.58M) | (99.41M) | (27.64M) | (38.1M) | (112.27M) |
| Pre-Tax Margin | -50.3% | -94.2% | -22.8% | -28.1% | -81.0% |
| Income Tax Expense | (36K) | 164K | 719K | 434K | (5.12M) |
| Net Income | (55.55M) | (99.57M) | (28.35M) | (38.53M) | (107.15M) |
| Net Margin | -50.2% | -94.4% | -23.4% | -28.4% | -77.3% |
| EPS (Basic) | (1.60) | (2.61) | (0.86) | (1.00) | (2.51) |
| EPS (Diluted) | (1.60) | (2.61) | (0.86) | (1.00) | (2.51) |
| Weighted Avg Shares | 36M | 36.99M | 37.59M | 38.37M | 42.64M |
| Weighted Avg Shares (Diluted) | 36M | 36.99M | 37.59M | 38.37M | 42.64M |
Quanterix Corporation
NASDAQ:QTRX
Intrinsic Alpha fair value
Locked
Current Price
$2.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.